Delving into the Latest Updates on VEGF (NIH) with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

VEGF (NIH)

Target

VEGFR

Mechanism

VEGFR agonists(Vascular endothelial growth factor receptor agonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication-

Inactive Indication

Peripheral Vascular Diseases

Originator Organization

National Institutes of Health

Active Organization-

Inactive Organization

National Institutes of Health

Drug Highest PhasePendingClinical

First Approval Date-

Regulation-

Two strawberry hemangiomas with positive estrogen receptor staining from 2 infants (cases 1 & 2) were used for HVECs culture. The HVECs of passage 3 were cultured in estrogen-free improved minimum essential medium and divided into 5 groups based on different treatments: group 1, no treatment; group 2, treated with E2; group 3, treated with VEGF; group 4, treated with both E2 and VEGF; group 5, treated with E2, VEGF, and TAM. Cell count (CC) and DNA proliferation index (PI) were determined on culture days 0, 3, 6, and 9.

RESULTS:

On day 9 in case 1, CC and PI were the following: in group 1, 1.15 +/- 0.18 x 10(5) mL and 19.96% +/- 1.45%, respectively, presenting no statistically significant changes; in group 2, 1.38 and 1.61 times those of group 1, respectively (P <.01); in group 3, 2.10 and 1.61 times those of group 2, respectively (P <.01); in group 4, 1.62 and 1.40 times as high as with group 3, respectively (P <.01); in group 5, down to the levels of group 1. The results in case 2 were similar to those in case 1.

CONCLUSIONS:

In vitro, the promoting effect of VEGF on HVECs proliferation is stronger than that of estrogen. Estrogen and VEGF enhance this proliferation in a synergistic fashion, which can be inhibited by tamoxifen.

WORLD JOURNAL OF UROLOGY

Systemic therapies and primary tumour downsizing in renal cell carcinoma: a real-world comparison of anti-angiogenic and immune checkpoint inhibition regimens

Article

Author: Yang, Yu-Hsuen ; Jackson-Spence, Francesca ; Flanders, Lucy ; Bex, Axel ; Powles, Thomas ; Toms, Charlotte ; Szabados, Bernadett ; Bickley, Leo Jurascheck ; Sng, Christopher

PURPOSE:

To investigate responses in the primary tumour to different systemic treatment regimens in patients with metastatic renal cell carcinoma (mRCC).

METHODS:

A single-centre retrospective analysis of treatment-naive mRCC patients without prior nephrectomy receiving VEGF tyrosine kinase inhibitors (VEGF only), immune checkpoint inhibitors (IO only), or combinations thereof (IO + VEGF). The primary outcome was the rate of partial response in the primary tumour (primary tumour PR, ≥ 30% diameter reduction). Secondary outcomes were time to best primary tumour diameter change, overall survival (OS) and progression-free survival (PFS) by Kaplan-Meier analysis. Predictors of survival outcomes were explored by Cox proportional hazards regression analysis.

RESULTS:

The rate of primary tumour PR was 14% for VEGF only (4/28 patients), 22% for IO only (5/23) and 50% for IO + VEGF (7/14), with median best primary tumour diameter change of - 8.0%, + 5.1%, and - 31.1% respectively, and median time to best primary tumour diameter change of 3.2, 3.0 and 6.9 months respectively. Median OS was significantly greater with IO + VEGF compared to VEGF only (HR 0.45, p = 0.04) and non-significantly greater compared to IO only (HR 0.46, p = 0.06). In multivariable analysis, primary tumour PR was the only response variable significantly associated with both OS (adjusted HR 0.32, p = 0.01) and PFS (adjusted HR 0.29, p < 0.01).

CONCLUSION:

mRCC patients without prior nephrectomy receiving first-line IO + VEGF regimens showed the greatest primary tumour responses, suggesting further prospective evaluation of this combination in the neoadjuvant and deferred cytoreductive nephrectomy settings.

100 Deals associated with VEGF (NIH)

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2022	Not Applicable	VEGF	-	VEGF	bgylvjfsky(vexqdnkziw) = wqchoqmsdo frltzipttp (mdqgqjbazh ) View more	-	01 May 2022
ERS2019	Not Applicable	Lymphangioleiomyomatosis VEGF	23	Patients treated with sirolimus	fhmbrtptaz(hssphlnehb) = ddchykcrcs vsrxnywrvq (kcpzhuvxec )	-	28 Sep 2019
ARVO2019	Not Applicable	Retinal Diseases vascular endothelial growth factor (VEGF)	-	VEGF	xxkfyomheo(hqlqxshpln) = iwvaptqtuo orunjlfmaz (lpmxpniwpi )	-	01 Jul 2019
ARVO2019	Not Applicable	Retinal Diseases vascular endothelial growth factor (VEGF)	-	VEGF	xxkfyomheo(hqlqxshpln) = xyankgthju orunjlfmaz (lpmxpniwpi )	-	01 Jul 2019
ARVO2009	Not Applicable	-	-	VEGF	qklensnkxi(eqojnpmezr) = tefkrqcxaj tdkwklxiov (cilhigmwnx )	-	01 Apr 2009
ARVO2004	Not Applicable	Retinal Vein Occlusion vascular endothelial growth factor (VEGF)	7	VEGF	dsnpaigqvw(gymimluqas) = ksjrvnrfhc gaaopgpioi (ipdfrgoscu, 0 - 552) View more	-	01 May 2004
ARVO2004	Not Applicable		7	VEGF	enoaweeuxf(xnhvixbzic) = yztrpfyoku cybstobilh (kcnrgerich )	-	01 May 2004
ARVO2004	Not Applicable	Retinal Diseases VEGF	-	VEGF	mjiojekcsp(uuymvdolsp) = gfzyucnavw pryxxgauir (ibkrcltgoe )	-	01 May 2004